Immunovant, Inc. - Common Stock (IMVT)

Structure Therapeutics advances oral therapies for chronic diseases, with a pipeline focused on metabolic and pulmonary conditions.

This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors.

This biotech firm develops therapies for urothelial cancers, leveraging proprietary delivery technology and a growing clinical pipeline.

Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Immunovant (NASDAQ:IMVT) reported a Q4 loss of 73 cents/share, missing estimates of 60 cents. R&D expenses rose to $142.3 million. Analysts adjust price targets.

Immunovant Inc (NASDAQ: IMVT) shares are trading higher Wednesday despite posting a wider-than-expected fourth‑quarter loss.

Roivant executives used the company’s fourth-quarter and fiscal-year earnings call to highlight new clinical data from its development portfolio, upcoming readouts and its strengthened balance sheet following a settlement with Moderna. Matthew Klein, CEO of Roivant, said the company has had “a pret

This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.

Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.

Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.

THOUSAND OAKS, Calif. – In a move that significantly strengthens its hold on the thyroid eye disease (TED) market, Amgen (NASDAQ: AMGN) recently announced pivotal Phase 3 topline results for its subcutaneous (SC) formulation of TEPEZZA (teprotumumab-trbw). The data, released on April 6, 2026, indicates that the subcutaneous version—delivered via

The biotechnology sector witnessed a seismic shift this week as Roivant Sciences (Nasdaq: ROIV) and its subsidiary Immunovant (Nasdaq: IMVT) reported a series of clinical and regulatory updates that have fundamentally reshaped the competitive landscape for autoimmune treatments. As of April 2, 2026, Roivant has reached a multi-year valuation peak,

This clinical-stage biotech develops antibody therapies targeting autoimmune diseases, with a lead candidate in Phase II trials.

Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]

Archer Aviation designs and manufactures electric aircraft for urban passenger transport, targeting the growing urban air mobility market.

This biotech specializes in antibody therapies for autoimmune diseases, with its lead candidate progressing through trials.

This digital media firm operates Truth Social, a platform delivering internet content and information services to online audiences.

As of February 26, 2026, the biotechnology sector is witnessing a historic maturation. For years, the industry narrative was dominated by high-burn, pre-revenue innovators searching for a "blockbuster" that could sustain their independence. Today, Argenx (NASDAQ: ARGX) has effectively ended that search, cementing its status as a global biopharmaceutical powerhouse. Following its full-year 2025 earnings [...]

Immunovant (IMVT) Q2 2025 Earnings Call Transcript

As of February 6, 2026, Roivant Sciences (Nasdaq: ROIV) has firmly established itself as the preeminent "capital allocator" of the biotechnology sector. The company made headlines today with a significant 15% stock surge, a move driven by clinical validation of its diversified "Vant" model. This recent rally—pushing shares toward a yearly high of $24.21—is primarily [...]